DBV Technologies reports positive Phase 3 data for its VIASKIN Peanut patch in children, supporting a planned U.S. BLA filing ...
The Aluminum Chemicals Market is propelled by rising demand across automotive, construction, packaging, and water treatment industries, where aluminum-based compounds offer high performance, corrosion ...
The so-called "Oroya fever" is an extremely severe infectious disease, yet it is classified among the so-called neglected ...
Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy ...
Since acquiring exclusive rights to launch and commercialise catumaxomab in 2024, in partnership with Lindis Biotech, Pharmanovia has been committed to ensuring people have access to a treatment that ...
News-Medical.Net on MSN
Mucus-inspired hydrogel resists stomach acid and promotes gastrointestinal healing
The Hong Kong Polytechnic University (PolyU) has developed an acid-resistant "ultra-stable mucus-inspired hydrogel" (UMIH), ...
A randomized controlled trial shows that the TNF inhibitor etanercept improves cerebral blood flow, vascular reactivity, and ...
With infertility affecting nearly one in five couples in India, stories like this highlight that when persistence, medical ...
Châtillon, France, December 16, 2025DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of ...
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, ...
The bacterial pathogen Bartonella bacilliformis causes in South America one of the most dangerous infectious diseases known: the so-called “Oroya fever.” Without antibiotic treatment, 90 percent of ...
The latest announcement is out from Amplia Therapeutics ( (AU:ATX) ).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback